Brief: Xilio Therapeutics, Inc. Q2 basic EPS USD -0.7
14/08/2023 14:35
Aug 14 (Reuters) - Xilio Therapeutics, Inc. Q2 operating expenses USD 20.116 million. * Q2 income from operations USD -20.116 million * Q2 basic EPS USD -0.7
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla